AMETEK(AME) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - AMETEK reported record sales of $2 billion in Q4 2025, a 13% increase from Q4 2024, with organic sales up 5% and acquisitions contributing 7% [4][5] - Operating income reached a record $523 million, up 12% year-over-year, with operating margins at 26.2% and core margins at 27.6%, an increase of 100 basis points [5][10] - Diluted earnings per share were a record $2.01, up 7% from the previous year, exceeding guidance [6][10] - Free cash flow was a record $527 million, up 6% year-over-year, with a conversion rate of 132% [6][22] Business Line Data and Key Metrics Changes - The Electronic Instruments Group (EIG) achieved sales of $1.37 billion, a 13% increase, with organic sales up 2% and acquisitions contributing 10 points [7] - The Electromechanical Group (EMG) reported sales of $629 million, up 15%, with organic sales up 14% and operating income increasing by 28% [9][10] Market Data and Key Metrics Changes - Overall orders increased by 18% to a record $2 billion, with organic orders up 7%, leading to a backlog of $3.58 billion [5][10] - U.S. and international sales were up mid-single digits, with Asia up 10%, driven by strong performance in China [41][42] Company Strategy and Development Direction - AMETEK announced the acquisition of LKC Technologies to enhance its med tech exposure, indicating a focus on strategic acquisitions to drive growth [4][12] - The company plans to invest an incremental $100 million in growth initiatives in 2026, building on a $90 million investment in 2025 [13] - AMETEK aims to maintain a disciplined approach to capital deployment, prioritizing acquisitions while also considering share repurchases and dividends [12][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate economic uncertainties and maintain strong performance, with expectations for mid- to high-single-digit sales growth in 2026 [17][18] - The company anticipates organic sales growth of low- to mid-single digits, with diluted earnings per share expected to rise 6%-9% [17][18] Other Important Information - AMETEK's effective tax rate for Q4 was 16.3%, with expectations for 2026 between 18.5% and 19.5% [20] - The company reported total debt of $2.3 billion, with cash and cash equivalents of $458 million, indicating a strong financial position [22][23] Q&A Session Summary Question: Can you provide insights into the medical portfolio performance? - Management noted that the broader healthcare exposure accounts for 21% of the business, with Paragon and Rauland showing low double-digit growth in Q4 and expected mid-single-digit growth in 2026 [25][26] Question: What is the outlook for strategic pricing going forward? - Management indicated a positive price-cost spread in Q4, with confidence in offsetting inflation and tariffs in 2026, supported by a differentiated product portfolio [27][28] Question: Can you discuss the performance of the process businesses? - The process businesses saw mid-teens growth in Q4, driven by recent acquisitions, with expectations for low single-digit organic growth in 2026 [35][36] Question: What is the status of the FARO acquisition? - Management expressed optimism about the FARO acquisition, highlighting synergies and the potential to improve EBITDA margins significantly over time [66][67] Question: How is the M&A pipeline looking for 2026? - Management reported a strong pipeline of high-quality acquisition candidates, with the capacity to deploy over $5 billion while maintaining an investment-grade credit rating [81][82]